Moreover, in the untreated and Plerixafor-treated tumors we detected more CD11b+/CD68+ cells respect to peptide R-treated gliomas, suggesting that peptide R treatment perturbs the activation state of GAMs. This evidence concerns the gene CD68 and central nervous system cancer.